-
公开(公告)号：US20240358816A1
公开(公告)日：2024-10-31
申请号：US18684529
申请日：2022-06-29
发明人： Erwin Van Den Born , Ian Jones
IPC分类号： A61K39/135 , A61K39/00 , A61P37/04 , C07K14/005 , C12N15/86
CPC分类号： A61K39/135 , A61P37/04 , C07K14/005 , C12N15/86 , A61K2039/5258 , C12N2710/14044 , C12N2770/32122 , C12N2770/32123 , C12N2770/32134 , C12N2770/32152 , C12N2770/32171
摘要： The present invention provides a recombinant foot and mouth disease virus (FMDV) capsid precursor protein comprising a modified VP1 protein and optionally further comprising a modified VP4 protein. The invention further relates to an isolated nucleic acid molecule and an expression vector comprising the nucleic acid molecule for recombinant expression of the modified capsid precursor protein. In further aspects, the invention relates to a virus-like particle (VLP) obtained from the modified capsid precursor protein and a vaccine for use in the protection of a subject against an infection with FMDV produced from the VLP.
-
2.发明申请公开(公告)号：US20120315295A1
公开(公告)日：2012-12-13
申请号：US13157097
申请日：2011-06-09
IPC分类号： A61K39/135 , C12N7/01 , C12Q1/70 , C07H21/04 , A61P31/14
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61K2039/55566 , C12N7/00 , C12N2770/32121 , C12N2770/32122 , C12N2770/32134 , C12N2770/32151 , C12N2770/32162 , C12N2770/32163 , C12N2770/32171 , C12Q1/701 , G01N33/56983 , G01N2469/10
摘要： We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
摘要翻译： 我们生成了新型分子标记的FMDV A24LL3DYR和A24LL3BPVKV3DYR疫苗候选物。 突变体病毒包含导致体内减毒的前导编码区（LL）的缺失和引入病毒非结构3Dpol和3B蛋白之一或两者的阴性抗原标记。 疫苗平台包括独特的限制性内切核酸酶位点，可以方便地交换不同FMDV亚型和血清型的衣壳蛋白。 突变体病毒不产生FMD的迹象，并且不会在牛中脱落毒性病毒。 没有观察到疾病或发烧的临床症状，并且在接种活A24LL3DYR的猪中未检测到接触动物的传播。 用化学灭活疫苗候选者免疫的牛显示出与多价商业FMDV疫苗相当的功效。 与cELISA一起使用的这些疫苗候选者为DIVA伴侣测试提供了合适的目标。
-
公开(公告)号：US09913891B2
公开(公告)日：2018-03-13
申请号：US15353727
申请日：2016-11-16
申请人： MERIAL INC.
IPC分类号： A61K48/00 , C12N15/85 , A61K38/19 , C07K14/535 , A61K38/18 , A61K39/135 , A61K39/385 , C07K14/005 , C12N7/00 , C07K14/32 , A61K39/00
CPC分类号： A61K39/135 , A61K39/385 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55566 , A61K2039/6075 , C07K14/005 , C07K14/32 , C07K2319/40 , C07K2319/735 , C12N7/00 , C12N2770/24222 , C12N2770/32122 , C12N2770/32134 , C12N2770/32171
摘要： The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
-
公开(公告)号：US20090264509A1
公开(公告)日：2009-10-22
申请号：US12117513
申请日：2008-05-08
IPC分类号： A61K31/7088 , C12N15/74 , A61P37/04
CPC分类号： A61K39/135 , A61K39/12 , A61K2039/5258 , A61K2039/552 , C12N15/86 , C12N2710/10343 , C12N2770/32134 , C12N2770/32171
摘要： The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.
摘要翻译： 本发明涉及一种腺病毒载体，其包含至少一个编码与促进剂可操作地连接的aphthovirus抗原和/或细胞因子的核酸序列。 腺病毒载体是复制缺陷型的，需要对腺病毒基因组的E1区域和E4区域的最多互补进行扩增。 本发明还涉及在哺乳动物中诱导免疫应答的方法，其包括向哺乳动物施用包含上述腺病毒载体的组合物。
-
公开(公告)号：US11952401B2
公开(公告)日：2024-04-09
申请号：US17375203
申请日：2021-07-14
发明人： Haixue Zheng , Fan Yang , Zixiang Zhu , Xiangle Zhang , Weijun Cao , Congcong Wang , Kangli Li , Huisheng Liu , Hong Tian , Keshan Zhang , Xiangtao Liu
IPC分类号： C07K14/005 , A61K39/00 , A61K39/135 , A61P31/14 , A61P37/06 , C12N7/00
CPC分类号： C07K14/005 , A61K39/135 , A61P31/14 , A61P37/06 , C12N7/00 , A61K2039/525 , A61K2039/552 , C12N2770/32121 , C12N2770/32122 , C12N2770/32134 , C12N2770/32152 , C12N2770/32171
摘要： The present disclosure belongs to the technical field of biological products for veterinary medicine, and specifically relates to a recombinant foot-and-mouth disease virus (FMDV) with a reduced immunosuppressive activity, a preparation method and use thereof, and a recombinant vaccine strain. According to the present disclosure, it is firstly discovered that FMDV 3B protein has an immunosuppressive function, and key sites for exerting the immunosuppressive function are found. A recombinant FMDV vaccine strain with a lost immunosuppressive function in FMDV 3B protein is constructed by introducing amino acid mutations into three repeated copies of FMDV 3B protein.
-
6.发明授权Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host 有权开发在天然宿主中减毒的标志物口蹄疫病毒疫苗候选物公开(公告)号：US08765141B2
公开(公告)日：2014-07-01
申请号：US13157097
申请日：2011-06-09
IPC分类号： A61K39/135 , C12N7/00 , C12N7/02 , C12N7/06 , C12N15/42
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61K2039/55566 , C12N7/00 , C12N2770/32121 , C12N2770/32122 , C12N2770/32134 , C12N2770/32151 , C12N2770/32162 , C12N2770/32163 , C12N2770/32171 , C12Q1/701 , G01N33/56983 , G01N2469/10
摘要： We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
摘要翻译： 我们生成了新型分子标记的FMDV A24LL3DYR和A24LL3BPVKV3DYR疫苗候选物。 突变体病毒包含导致体内减毒的前导编码区（LL）的缺失和引入病毒非结构3Dpol和3B蛋白之一或两者的阴性抗原标记。 疫苗平台包括独特的限制性内切核酸酶位点，可以方便地交换不同FMDV亚型和血清型的衣壳蛋白。 突变体病毒不产生FMD的迹象，并且不会在牛中脱落毒性病毒。 没有观察到疾病或发烧的临床症状，并且在接种活A24LL3DYR的猪中未检测到接触动物的传播。 用化学灭活疫苗候选者免疫的牛显示出与多价商业FMDV疫苗相当的功效。 与cELISA一起使用的这些疫苗候选者为DIVA伴侣测试提供了合适的目标。
-
公开(公告)号：US20180169216A1
公开(公告)日：2018-06-21
申请号：US15888718
申请日：2018-02-05
申请人： Merial Inc.
IPC分类号： A61K39/135 , A61K39/385 , C07K14/005 , C07K14/32 , C12N7/00 , A61K39/00
CPC分类号： A61K39/135 , A61K39/385 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55566 , A61K2039/6075 , C07K14/005 , C07K14/32 , C07K2319/40 , C07K2319/735 , C12N7/00 , C12N2770/24222 , C12N2770/32122 , C12N2770/32134 , C12N2770/32171
摘要： The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
-
公开(公告)号：US20180080042A1
公开(公告)日：2018-03-22
申请号：US15288935
申请日：2016-10-07
发明人： Shun-Wen KO
IPC分类号： C12N15/86 , C12N15/87 , G01N33/569 , G01N33/577 , A61K39/215 , A61K39/12 , A61K39/135
CPC分类号： C12N15/86 , A61K39/00 , A61K39/12 , A61K39/135 , A61K39/215 , A61K2039/5156 , A61K2039/545 , A61K2039/552 , A61P31/14 , A61P31/20 , C07K16/10 , C07K16/1009 , C12N15/87 , C12N2710/24122 , C12N2710/24134 , C12N2710/24143 , C12N2710/24152 , C12N2710/24171 , C12N2750/10034 , C12N2750/10071 , C12N2770/20034 , C12N2770/20071 , C12N2770/32134 , C12N2770/32171 , G01N33/554 , G01N33/56983 , G01N33/577 , G01N2333/01 , G01N2333/09 , G01N2333/165 , G01N2800/26
摘要： A mammalian cell co-transfect with an expression plasmid comprising T7 promoter and an open reading frame (ORF) of target antigen, and a vT7 recombinant vaccinia virus expressing T7 polymerase. The entire antigen expressing cell is used as a carrier of the target antigen for preparing a vaccine or diagnostic agent, and screening monoclonal antibodies.
-
公开(公告)号：US20170143819A1
公开(公告)日：2017-05-25
申请号：US15353727
申请日：2016-11-16
申请人： MERIAL INC.
IPC分类号： A61K39/135 , C07K14/005 , C12N7/00 , A61K39/385
CPC分类号： A61K39/135 , A61K39/385 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55566 , A61K2039/6075 , C07K14/005 , C07K14/32 , C07K2319/40 , C07K2319/735 , C12N7/00 , C12N2770/24222 , C12N2770/32122 , C12N2770/32134 , C12N2770/32171
摘要： The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
-
10.发明授权Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host 有权开发在天然宿主中减毒的标志物口蹄疫病毒疫苗候选物公开(公告)号：US09180179B1
公开(公告)日：2015-11-10
申请号：US14280984
申请日：2014-05-19
IPC分类号： G01N33/569 , A61K39/135 , C12N7/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61K2039/55566 , C12N7/00 , C12N2770/32121 , C12N2770/32122 , C12N2770/32134 , C12N2770/32151 , C12N2770/32162 , C12N2770/32163 , C12N2770/32171 , C12Q1/701 , G01N33/56983 , G01N2469/10
摘要： We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
摘要翻译： 我们生成了新型分子标记的FMDV A24LL3DYR和A24LL3BPVKV3DYR疫苗候选物。 突变体病毒包含导致体内减毒的前导编码区（LL）的缺失和引入病毒非结构3Dpol和3B蛋白之一或两者的阴性抗原标记。 疫苗平台包括独特的限制性内切核酸酶位点，可以方便地交换不同FMDV亚型和血清型的衣壳蛋白。 突变体病毒不产生FMD的迹象，并且不会在牛中脱落毒性病毒。 没有观察到疾病或发烧的临床症状，并且在接种活A24LL3DYR的猪中未检测到接触动物的传播。 用化学灭活疫苗候选者免疫的牛显示出与多价商业FMDV疫苗相当的功效。 与cELISA一起使用的这些疫苗候选者为DIVA伴侣测试提供了合适的目标。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.019 秒)
